Advertisement
UK markets open in 47 minutes

  • NIKKEI 225

    39,702.32
    +529.17 (+1.35%)
     

  • HANG SENG

    18,110.35
    +37.45 (+0.21%)
     

  • CRUDE OIL

    81.29
    +0.46 (+0.57%)
     

  • GOLD FUTURES

    2,322.80
    -8.00 (-0.34%)
     

  • DOW

    39,112.16
    -299.05 (-0.76%)
     

  • Bitcoin GBP

    48,509.89
    +434.79 (+0.90%)
     

  • CMC Crypto 200

    1,279.00
    -4.78 (-0.37%)
     

  • NASDAQ Composite

    17,717.65
    +220.84 (+1.26%)
     

  • UK FTSE All Share

    4,493.07
    -21.69 (-0.48%)
     
Money:

How to save for a good retirement income

Saving for retirement is a huge challenge, but for millions of people the key rests in their bank accounts

Celcuity To Participate in Jefferies Global Healthcare Conference

Celcuity Inc.
·2-min read
Celcuity Inc.
Celcuity Inc.

MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024.

Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the event will be available using this weblink https://wsw.com/webcast/jeff302/celc/1809904. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.

About Celcuity 
Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is enrolling patients. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is expected to begin enrolling patients in the second quarter of 2025. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and  Twitter.

ADVERTISEMENT

View source version of release on GlobeNewswire.com

Contacts: 
Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123

ICR Westwicke 
Maria Yonkoski, maria.yonkoski@westwicke.com   
(203) 682-7167